News

Charles River Laboratories International, Inc. (NYSE: CRL) and the Gates Institute at the University of Colorado Anschutz Medical Campus today announced a lentiviral vector contract development and manufacturing organization (CDMO) agreement. Gates Institute will leverage Charles River’s premier cell and gene therapy CDMO expertise to develop Good Manufacturing Practice (GMP)-grade lentiviral vectors (LVVs) for use…

Colorado Tech Spotlight features a profile of GelSana and how this Fitzsimons Innovation Community company is disrupting the field of wound care. Discover how it works, the story behind it, and how the Colorado life sciences and medical technology community comes together to collaborate and grow our state’s prominence in the field.

CellSight researchers have been granted funding from the National Institutes of Health to better understand retinal cells differentiation and mechanisms for successful stem cell-derived 3D retinal transplants in patients with age-related macular degeneration (AMD).

Fitzsimons Innovation Community is expanding life sciences innovation in the region with an updated mater plan for the 184-acre innovation campus to the north of the world-renowned University of Colorado Anschutz Medical Center. The innovation community is currently home to more than 80 visionary companies taking their research to the next level to cure disease,…

Focusing on non-addictive treatments for chronic pain and addiction, Lohocla Research Corporation gets the go-ahead for first-in-human trials of their first-in-class therapeutic for chronic pain syndromes.

A group of 22 partners representing Colorado’s life sciences ecosystem have banded together to fund a new national economic development campaign to bolster Colorado into “America’s epicenter for life sciences innovation.”

For health care and life sciences companies beginning the search for a new facility to call home, innovation communities are often sought-after destinations.

GelSana, a Fitzsimons Innovation Community member company, will focus their efforts on the development of novel wound dressing polymers for the care of combat-related burn injuries.

Announced on the stage at ViVE 2024, EntroTrack was selected for the inaugural cohort from a robust list of startup applicants aiming to reduce the burden of cancer for all people.

Record levels of funding propel Denver-Boulder to the top of the life sciences market.